New pill shows promise for tough bladder cancer cases
NCT ID NCT07185945
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental daily pill called zanzalintinib in 44 adults with advanced bladder cancer that has continued to grow after previous treatments. The goal is to see if the drug can shrink tumors or slow the cancer's progression. Participants will take the pill once a day and have regular scans to monitor their response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for advanced bladder cancer? bevacizumab combo tested
- New combo therapy for tough bladder cancer cases shows early promise
- New bladder cancer drug SYS6002 takes on PADCEV in Head-to-Head trial
- New drug combo targets tough cancers in early trial
- New targeted drug aims to fight hard-to-treat bladder cancers
- New drug cocktail targets Hard-to-Treat bladder cancer